Literature DB >> 11752654

Lnk adaptor: novel negative regulator of B cell lymphopoiesis.

C E Rudd1.   

Abstract

Originally thought to have the functions now ascribed to the linker for activation of T cells protein (LAT), Lnk is coming into its own as an adaptor protein that mediates signaling through several receptor pathways. An essential role for Lnk in B cell development and maturation was recently uncovered by Perlmutter and colleagues. Rudd discusses the role of Lnk in B cells and hypothesizes a mechanism whereby Lnk, and its closely related protein family members, the adaptor molecules containing pleckstrin homology (PH) and Src-homology 2 (SH2) domains (APS), and Src-homology 2-B protein (SH2-B), may mediate signal promotion or attenuation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11752654     DOI: 10.1126/stke.2001.85.pe1

Source DB:  PubMed          Journal:  Sci STKE        ISSN: 1525-8882


  16 in total

1.  Lnk constrains myeloproliferative diseases in mice.

Authors:  Alexey Bersenev; Chao Wu; Joanna Balcerek; Jiang Jing; Mondira Kundu; Gerd A Blobel; Kudakwashe R Chikwava; Wei Tong
Journal:  J Clin Invest       Date:  2010-05-10       Impact factor: 14.808

Review 2.  Normal and malignant megakaryopoiesis.

Authors:  Qiang Wen; Benjamin Goldenson; John D Crispino
Journal:  Expert Rev Mol Med       Date:  2011-10-21       Impact factor: 5.600

3.  Genetic loss of SH2B3 in acute lymphoblastic leukemia.

Authors:  Arianne Perez-Garcia; Alberto Ambesi-Impiombato; Michael Hadler; Isaura Rigo; Charles A LeDuc; Kara Kelly; Chaim Jalas; Elisabeth Paietta; Janis Racevskis; Jacob M Rowe; Martin S Tallman; Maddalena Paganin; Giuseppe Basso; Wei Tong; Wendy K Chung; Adolfo A Ferrando
Journal:  Blood       Date:  2013-08-01       Impact factor: 22.113

4.  ROS-mediated amplification of AKT/mTOR signalling pathway leads to myeloproliferative syndrome in Foxo3(-/-) mice.

Authors:  Safak Yalcin; Dragan Marinkovic; Sathish Kumar Mungamuri; Xin Zhang; Wei Tong; Rani Sellers; Saghi Ghaffari
Journal:  EMBO J       Date:  2010-11-26       Impact factor: 11.598

5.  Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.

Authors:  Stephen T Oh; Erin F Simonds; Carol Jones; Matthew B Hale; Yury Goltsev; Kenneth D Gibbs; Jason D Merker; James L Zehnder; Garry P Nolan; Jason Gotlib
Journal:  Blood       Date:  2010-04-19       Impact factor: 22.113

6.  Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F.

Authors:  Sigal Gery; Qi Cao; Saskia Gueller; Hongtao Xing; Ayalew Tefferi; H Phillip Koeffler
Journal:  J Leukoc Biol       Date:  2009-03-17       Impact factor: 4.962

7.  Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis.

Authors:  Wei Tong; Harvey F Lodish
Journal:  J Exp Med       Date:  2004-08-30       Impact factor: 14.307

8.  Regulation of lifespan, metabolism, and stress responses by the Drosophila SH2B protein, Lnk.

Authors:  Cathy Slack; Christian Werz; Daniela Wieser; Nazif Alic; Andrea Foley; Hugo Stocker; Dominic J Withers; Janet M Thornton; Ernst Hafen; Linda Partridge
Journal:  PLoS Genet       Date:  2010-03-19       Impact factor: 5.917

9.  Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2.

Authors:  Alexey Bersenev; Chao Wu; Joanna Balcerek; Wei Tong
Journal:  J Clin Invest       Date:  2008-08       Impact factor: 14.808

10.  When the Brakes are Lost: LNK Dysfunction in Mice, Men, and Myeloproliferative Neoplasms.

Authors:  Stephen T Oh
Journal:  Ther Adv Hematol       Date:  2011-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.